19-08-2010: CEVEC Pharmaceuticals announced the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community. Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed. CEVEC will continue to expand its global license business of the CAP® and CAP-T® technologies for commercial use and industrial development purposes.
CEVEC’s transient CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.
Life Technologies combines CEVEC’s proprietary protein expression system based on CAP cells with its tailored protein expression product portfolio (media, transfection reagents etc.) to enable research scientists worldwide to achieve highest yield and quality protein expression.
CEVEC Pharmaceuticals (CEVEC), the developer of the CAP® Technology, a novel human expression system derived from amniocytes, and VPM – Vakzine Projekt Management GmbH announced the signing of an license agreement on VPM’s proprietary human CMV dense body technology.
CAP® Technology is base ... more
CEVEC Pharmaceuticals, licensing its human CAP® Technology based expression system for proteins and vaccines, announced the closing of a €6M financing round. NRW.BANK and Creathor Venture Fonds led this round which included the participation from current investors, a group of private and in ... more
CEVEC Pharmaceuticals and Catalent Pharma Solutions announced a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s GPEx® (Gene Product Expression) Technolog ... more
Thermo Fisher Scientific and Life Technologies Corporation have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of net debt at close ($2.2 billion as ... more
BAC BV has announced a strategic collaboration with Life Technologies to bring the wide range of BAC’s CaptureSelect® affinity ligand specificities to Life Technologies’ POROS® chromatography media and pre-packed HPLC columns. The collaboration will create a range of ready-to-use HPLC col ... more
Life Technologies Corporation announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine (PGM™) strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hy ... more
Life Technologies is a global biotechnology tools company dedicated to improving the human condition. Its systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies custom ... more